Correlation of DPP4 enzyme with SARS-CoV-2 infection
DOI:
https://doi.org/10.33448/rsd-v10i13.21361Keywords:
Enzyme; Dipeptidyl peptidase 4; COVID-19; Glucose.Abstract
COVID-19 has become a high-risk issue of global concern. The glycoprotein (S) peak in the virion envelope is proteolytically cleaved into the S1 and S2 subunits, and receptor recognition is mediated by receptor binding domain (RBD) and membrane fusion. This is a literature review of a qualitative nature based on scientific production from studies published between 2019 and 2021 that addressed the main objective of this study to correlate DPP4 in SARS-CoV-2 infection. Coronavirus tropism mainly depends on the ability of the glycoprotein (S) entry peak to bind to cell surface receptors. It is currently reported that SARS-CoV-2 can use angiotensin-2 converting enzyme (ACE2), the same receptor as SARS-CoV, to infect humans. However, recent evidence suggests that SARS-CoV-2 binds to DPP4/CD26 after entering airway cells. It appears that the interaction between the peak glycoprotein SARS-CoV-2 and human DPP4/CD26 (also known as dipeptidyl peptidase-4 (DPP4) is a key factor in sequestration and virulence. In the absence of results from well-designed randomized clinical trials, the efficacy or safety data of DPP4 inhibitors in the treatment of COVID-19 must be interpreted with caution and no clear conclusions can be drawn.The results of these studies may help reveal the impact of using drugs that inhibit DPP4 and whether they can be effective in the treatment of COVID-19 infection.
References
Bassendine, M. F, Bridge, S. H, McCaughan, G. W & Gorrell, M. D (2020). COVID ‐ 19 e comorbidades: Um papel da dipeptidil peptidase 4 (DPP4) na gravidade da doença? Journal of diabetes, 12 (9), 649-658.
Bonora, B. M, Avogaro, A., & Fadini, G. P (2021). Desembaraçando evidências conflitantes sobre os inibidores DPP-4 e os resultados do COVID-19: revisão narrativa e meta-análise. Journal of Endocrinological Investigation , 1-8.
Du, H., Wang, D. W & Chen, C. (2020). Os efeitos potenciais dos inibidores DPP-4 no sistema cardiovascular em pacientes COVID-19. Journal of Cellular and Molecular Medicine, 24 (18), 10274-10278.
Iacobellis, G. (2020). COVID-19 e diabetes: a inibição de DPP4 pode desempenhar um papel? Pesquisa e prática clínica sobre diabetes, 162.
Khin, P. P., Cha, S. H., Jun, H. S., & Lee, J. H. (2020). A potential therapeutic combination for treatment of COVID-19: synergistic effect of DPP4 and RAAS suppression. Medical hypotheses, 144, 110-186.
Kow, C. S & Hasan, S. S (2020). Uma meta-análise sobre o uso de inibidores da DPP-4 antes da admissão e o risco de um curso grave ou fatal da doença em pacientes com COVID-19. Therapie .
Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., & Lu, J. (2020). The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. Iscience, 23(6), 101-160.
Marinho, F. P., de Loyola, I. S., Monteiro, I. D. O. F., Castro, T. M., de Souza Carvalho, M. D. G., Garcia, J. A. D., & Santos, G. B. (2021). Inter-relação entre COVID-19 e diabetes mellitus: uma revisão sistemática. Research, Society and Development, 10(2), e4810212191-e4810212191.
Noh, Y., Oh, I. S, Jeong, H. E, Filion, K. B, Yu, O. H. Y, & Shin, J. Y (2021). Associação entre inibidores DPP-4 e desfechos relacionados ao COVID-19 entre pacientes com diabetes tipo 2. Cuidados com a diabete, 44 (4), e64-e66.
Pinheiro, M. M, Fabbri, A., & Infante, M. (2021). Modulação de tempestade de citocinas em COVID-19: um papel proposto para a terapia combinada de vitamina D e inibidor de DPP-4 (VIDPP-4i). Immunotherapy, 13 (9), 753-765.
Schlicht, K., Rohmann, N., Geisler, C., Hollstein, T., Knappe, C., Hartmann, K., & Laudes., M. (2020). Os níveis circulantes de dipeptidilpeptidase-4 solúvel são reduzidos em seres humanos hospitalizados por infecções graves por COVID-19. International Journal of Obesity , 44 (11), 2335-2338.
Solerte, S. B, Di Sabatino, A., Galli, M., & Fiorina, P. (2020). Inibição da dipeptidil peptidase-4 (DPP4) em COVID-19. Acta diabetologica, 57, 779-783.
Strollo, R. & Pozzilli, P. (2020). Inibição de DPP4: prevenção da infecção por SARS ‐ CoV ‐ 2 e / ou progressão de COVID ‐ 19? Pesquisa e revisões sobre diabetes / metabolismo, 36 (8), e3330.
Trzaskalski, N. A, Fadzeyeva, E., & Mulvihill, E. & (2020). Dipeptidil peptidase-4 na interface entre a inflamação e o metabolismo. Clinical Medicine Insights: Endocrinology and Diabetes , 13 , 1179551420912972.
Vieira, G. D. V., de Lucas Xavier, J. O., de Oliveira Freitas, J. C., & de Sousa, O. V. (2020). Agonistas do receptor de GLP-1 e inibidores da serino-protease dipeptidil-peptidase-4 no tratamento de diabetes tipo 2-Uma revisão. Brazilian Journal of Health Review, 3(4), 7654-7675.
Yang, Y., Cai, Z., & Zhang, J. (2021). Os inibidores DPP-4 podem melhorar a mortalidade da doença coronavírus 2019: Uma meta-análise. PloS one, 16 (5), e0251916.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Lennara Pereira Mota; Maria Vitalina Alves de Sousa; Maria Jandeline do Nascimento Silva; Amanda Eckhardt ; Domennique Miranda Vasconcelos; Lyrlanda Maria Cavalcante de Almeida; Juliana Maria de Freitas; Alexandra Rodrigues Cardoso; Annyelli Victória Moura Oliveira; João Pedro Tavares de Oliveira; Francilene Vieira da Silva Freitas; Ana Alinne Gomes da Penha; Eldson Rodrigues Borges; Joice Mara Ferreira dos Santos; Beatriz Caroline Leão Lima; Andressa Dâmaras Freitas Feitosa; Iaggo Henrique de Sousa Figueiredo; Emanuelle da Costa Gomes ; Geovana Marques Teixeira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
